{
  "docId": "019de070-7de1-7343-8d2f-5d51a9877c50",
  "docSlug": "ff3158b4501b6094038126272ca46097",
  "documentTitle": "BioAtla | IPO Presentation Deck | 31 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 22,
  "pageCount": 31,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses a comparison table to contrast monotherapy with combination therapy, highlighting the trade-off between improved survival and increased adverse events.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-7de1-7343-8d2f-5d51a9877c50/22",
  "deckHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50",
  "deckJsonHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50.json",
  "deckAnchorHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.25,
        "y": 0.82
      },
      "kind": "callout",
      "text": "Global collaboration with BeiGene in place to maximize value",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10fd1c5f-ff10-411a-8362-2c3aa408ce84",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "Outcomes: Traditional combination of anti-PD-1 and anti-CTLA-4 checkpoint inhibitor led to improved outcomes. Adverse Events: Combination associated with increase in adverse events and treatment discontinuations. Unmet Need: A safe combo of PD-1/CTLA-4 has potential across many immunogenic tumors.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c0586295-34f3-4bf1-b4a0-bcb2c253e982",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "Usage and dosage of ipilimumab (CTLA-4 inhibitor) highly limited due to its safety profile (average # of cycles on therapy does not exceed 4 cycles). Ipilimumab dose in combination with Nivolumab is 1/3 to 1/10 the monotherapy level, but still results in high toxicity.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8eab813f-3cf0-4dfa-855c-088ba1f2d87b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: 'Larkin et al., New Eng. J. Med., 373: 23-34, 2015",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "447b9206-652b-46c6-8c26-1f9f72478763",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.38
      },
      "kind": "table",
      "text": "Clinical Endpoint | Nivolumab (PD-1) | Nivolumab (PD-1) + Ipilimumab (CTLA-4) | Progression Free Survival: 6.9 months vs 11.5 months | Grade 3 or 4 Adverse Events: 16.3% vs 55.0% | Discontinued Treatment: 7.7% vs 36.4%",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "288cf933-9314-4a41-8646-7a4c4c868af4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "Opportunity exists for a “safer” CTLA-4 inhibitor",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31125f88-0427-4499-bcb0-2ea2a4abc693",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "CAB CTLA-4: Potential for Disruption of the I/O Market",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d8dc6bb-5de1-458b-bf84-4ec11d30c2f2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "a1db77ff-34a6-4190-b7a1-91204ab1ffd3",
      "evidence": "The slide describes a problem and its consequences, fitting the problem statement canvas.",
      "confidence": 0.7
    },
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "6d323275-40ac-4fbf-a66e-536fae6ca9ea",
      "evidence": "The slide contains a table/data component with clinical endpoint information.",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "ad00d7b9-8ab6-4789-b7d7-39269cf0bd81",
      "evidence": "Contrasts current high-toxicity standard of care with the potential for a safer alternative.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 22,
      "from": 22,
      "beatId": "53fe639c-818d-4491-8256-844c4c66c261",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The document presents a clear problem statement on page 22.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 30,
      "from": 22,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "426c9e34-7091-4e35-85fe-e86bd0b5fb99",
      "evidence": "The document implies the cost of inaction by presenting the potential benefits of BioAtla's technology.",
      "position": 0,
      "objective": "What is the cost of not adopting BioAtla's technology?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}